• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Virus Evol . The evolutionary history of ACE2 usage within the coronavirus subgenus Sarbecovirus

tetano

Editor, Senior Moderator
Virus Evol


. 2021 Feb 5;7(1):veab007.
doi: 10.1093/ve/veab007. eCollection 2021 Jan.
The evolutionary history of ACE2 usage within the coronavirus subgenus Sarbecovirus


H L Wells[SUP] 1 [/SUP], M Letko[SUP] 2 3 [/SUP], G Lasso[SUP] 4 [/SUP], B Ssebide[SUP] 5 [/SUP], J Nziza[SUP] 5 [/SUP], D K Byarugaba[SUP] 6 7 [/SUP], I Navarrete-Macias[SUP] 8 [/SUP], E Liang[SUP] 8 [/SUP], M Cranfield[SUP] 9 10 [/SUP], B A Han[SUP] 11 [/SUP], M W Tingley[SUP] 12 [/SUP], M Diuk-Wasser[SUP] 1 [/SUP], T Goldstein[SUP] 9 [/SUP], C K Johnson[SUP] 9 [/SUP], J A K Mazet[SUP] 9 [/SUP], K Chandran[SUP] 4 [/SUP], V J Munster[SUP] 3 [/SUP], K Gilardi[SUP] 6 9 [/SUP], S J Anthony[SUP] 13 [/SUP]



Affiliations

Abstract

Severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) and SARS-CoV-2 are not phylogenetically closely related; however, both use the angiotensin-converting enzyme 2 (ACE2) receptor in humans for cell entry. This is not a universal sarbecovirus trait; for example, many known sarbecoviruses related to SARS-CoV-1 have two deletions in the receptor binding domain of the spike protein that render them incapable of using human ACE2. Here, we report three sequences of a novel sarbecovirus from Rwanda and Uganda that are phylogenetically intermediate to SARS-CoV-1 and SARS-CoV-2 and demonstrate via in vitro studies that they are also unable to utilize human ACE2. Furthermore, we show that the observed pattern of ACE2 usage among sarbecoviruses is best explained by recombination not of SARS-CoV-2, but of SARS-CoV-1 and its relatives. We show that the lineage that includes SARS-CoV-2 is most likely the ancestral ACE2-using lineage, and that recombination with at least one virus from this group conferred ACE2 usage to the lineage including SARS-CoV-1 at some time in the past. We argue that alternative scenarios such as convergent evolution are much less parsimonious; we show that biogeography and patterns of host tropism support the plausibility of a recombination scenario, and we propose a competitive release hypothesis to explain how this recombination event could have occurred and why it is evolutionarily advantageous. The findings provide important insights into the natural history of ACE2 usage for both SARS-CoV-1 and SARS-CoV-2 and a greater understanding of the evolutionary mechanisms that shape zoonotic potential of coronaviruses. This study also underscores the need for increased surveillance for sarbecoviruses in southwestern China, where most ACE2-using viruses have been found to date, as well as other regions such as Africa, where these viruses have only recently been discovered.

Keywords: coronavirus; recombination; viral ecology; virus evolution.
 
Back
Top Bottom